AstraZeneca cutbacks underscore outsourcing movement

AstraZeneca's decision to cut another 2,200 jobs out of its R&D ops is underscoring a shift from in-house work to a greater reliance on external ties. As AstraZeneca ($AZN) finds itself under severe pressure from falling profits, the pharma giant has decided to go "virtual" on its neuroscience work. And that will speed the industry trend toward outsourcing more discovery and development work to its academic and industry partners. Story

Suggested Articles

The coronavirus is now putting a strain on CROs and researchers in affected areas.

Synteract has boosted its reach into the Asia-Pacific region and South Africa after snapping up a specialty biometrics CRO.

It’s a tale as old as time: Drug development can be a slow, expensive and laborious task and, more often than not, yields failure.